Cipla Limited delivered a strong set of numbers in the second quarter of fiscal 2024 and also outlined pipeline promise, though uncertainty and ongoing speculation around a potential stake sale by the promoter group may be fueling some “distraction” across the ranks. (see side box)
Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’
"Very small investment” in gene editing/sequencing on cards
Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.
More from Business
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.